Plasma Therapy Market Size, Share & Industry Analysis, By Type (Pure PRP, Leukocyte-rich PRP Pure Platelet-Rich Fibrin (PRF), and Leukocyte-rich Fibrin (L-PRF)), By Sources (Autologous, and Allogenic), By Application (Wound Care, Dermatology & Aesthetics, Orthopedics, and Others), By End User (Hospitals & ASCs, Specialty Clinics, Research Institutes, and Others), and Regional Forecast, 2026-2034

The global plasma therapy market size was valued at USD 620.0 million in 2025. The market is projected to grow from USD 669.6 million in 2026 to USD 1,194.2 million by 2034, exhibiting a CAGR of 7.50% during the forecast period.

The global plasma therapy market is experiencing steady and substantial growth. It involves processing the patient's blood to concentrate platelets and then injecting this plasma into affected areas to promote healing. It is used to treat joint injuries by accelerating tissue repair and regeneration. In dermatology, it is used to assist with skin rejuvenation, acne scar treatment, and hair restoration. For wound care, plasma therapy enhances tissue regeneration and reduces healing time for chronic or difficult wounds. 

Thus, the rising prevalence of orthopedic and wound injuries, along with increasing disposable income for aesthetic procedures, is expected to boost market growth during the forecast period.

• For instance, according to the National Safety Council, in 2024, 4.4 million people were treated in emergency departments for injuries involving sports and recreational equipment.

Many key industry players, such as Stryker and Zimmer Biomet, operating in the market, have a strong product portfolio, established surgeon relationships, and extensive distribution networks that help scale therapy adoption.

PLASMA THERAPY MARKET TRENDS

Increasing Launch of PRP Preparation Systems is a Key Market Trend

The increasing launch of PRP (Platelet-Rich Plasma) preparation systems is a significant trend in the global plasma therapy market in the plasma therapy sector, which is driven by the rising demand for minimally invasive treatments that utilize autologous blood components to promote tissue regeneration and healing. Additionally, there is an increasing demand for advanced PRP systems that offer improved efficiency, higher-quality plasma, and ease of use, catering to both clinical and aesthetic applications. Overall, this trend reflects the increasing emphasis on personalized regenerative medicine and the continuous development of innovative plasma-based therapies.

• For instance, in September 2025, Smith+Nephew launched the CENTRIO Platelet-Rich-Plasma (PRP) System, a biodynamic hematogel derived from a patient’s own platelets and plasma, which assists the natural healing process by maintaining a moist wound environment.

Download Free sample to learn more about this report.

MARKET DYNAMICS

MARKET DRIVERS

Rising Burden of Musculoskeletal Disorders to Drive Market Growth

The increasing prevalence of musculoskeletal disorders (MSDs) is significantly contributing to the global plasma therapy market growth. As conventional treatments often provide limited relief and may involve invasive procedures, there is a growing demand for regenerative therapies, such as platelet-rich plasma (PRP) therapy. These therapies can reduce pain, improve joint function, and accelerate recovery times.

• For instance, according to the World Health Organization's July 2022 report, approximately 1.71 billion people worldwide have musculoskeletal conditions, with these conditions being most common among elderly patients, affecting nearly three out of four people aged 65 and older.

MARKET RESTRAINTS

Availability of Alternate Treatment to Limit Market Growth

One of the restraining factors in the market is the availability of alternative treatments to plasma therapy. As newer therapies, such as monoclonal antibodies, antiviral drugs, and other biologics, become more accessible and proven effective, the reliance on plasma therapy reduces. The availability of Botox, stem cell therapy, hyaluronic acid injections, and traditional surgical methods also offers competing solutions, thereby restraining the market's growth.

• For instance, in January 2025, Vertex Pharmaceuticals announced that the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a non-opioid analgesic, for the treatment of moderate to severe acute pain in adults.

MARKET OPPORTUNITIES

Expanding Application Areas in Aesthetic & Dermatology Procedures to Offer Lucrative Growth Opportunities in the Market

Expanding application areas for plasma therapy offer a significant growth opportunity in the market. As demand for safe, minimally invasive solutions increases, the shift toward innovative plasma-based treatments, such as skin rejuvenation, scar reduction, anti-aging, and hair treatment, is underway. Additionally, the adoption of these therapies in aesthetic and hair clinics is expected to boost market growth.

• For instance, in December 2023, Hairline International Hair and Skin Clinic introduced an advanced hair regeneration therapy called Sonicated PRP, which is based on groundbreaking research utilizing platelet-rich plasma (PRP) to activate and regenerate hair follicles.

MARKET CHALLENGES

High Costs Associated with Therapy to Challenge Market Growth

The high cost associated with therapy hinders adoption in lower-income countries, thus challenging market growth. The high cost associated with plasma collection, processing, and storage significantly increases the overall treatment cost, limiting accessibility for many patients. Additionally, these therapies require expensive infrastructure and specialized equipment, further hindering the widespread adoption of plasma-based therapies.

Segmentation Analysis

By Type

Pure PRP Segment to Lead due to Its Widespread Adoption

Based on type, the market is categorized into pure PRP, leukocyte-rich PRP, pure platelet-rich fibrin (PRF), and leukocyte-rich fibrin (L-PRF).

The pure PRP segment is expected to account for the largest share of the plasma therapy market. The pure PRP segment held a 45.1% market share, driven by its widespread adoption across major areas, particularly in orthopedics, sports medicine, and dermatology & aesthetics. It is also easier to prepare and standardize in routine outpatient workflows, thus boosting the adoption and the segment’s growth.

• For instance, in June 2023, Isto Biologics introduced Precise, an innovative, cutting-edge technology that provides a final PRP product with accurate cellular fractions through concentration. The Precise system's CellectFlex Technology enables the creation of customized cell compositions during each spin.

The pure platelet-rich fibrin (PRF) segment is expected to grow at a CAGR of 10.85% over the forecast period. 

To know how our report can help streamline your business, Speak to Analyst

By Sources

Autologous Segment Led the Market due to its Beneifts

As per the sources, the market is segmented into autologous and allogeneic.

In 2025, the autologous segment dominated the global market. The autologous segment dominated the market, accounting for a 95.4% plasma therapy market share. The dominant share of the segment is driven by the benefits associated with autologous sources, as they are simpler to handle and have a lower immunologic risk. Addtionally, the therapy is commonly prepared at the point of care from the patient’s own blood, making it readily available for routine use in orthopedics, aesthetics, and dental workflows. Moreover, the launch of new devices for autologous preparations is expected to boost the segment’s growth.

• For instance, in December 2025, Croma Pharma launched a new medical device used for preparing autologous Platelet-Rich Plasma (PRP) and Fluid-Platelet-Rich Fibrin (Fluid-PRF).

The allogenic segment is projected to grow at a CAGR of 11.18% over the forecast period. 

By Application

Increasing Number of Burn Injuries Boosted Wound Care Segment Expansion

Based on application, the market is segmented into wound care, dermatology & aesthetics,

orthopedics, and others.

The wound care segment held a major portion of the market, accounting for a 45.3% share of the total segment. The increasing number of burn injuries, ulcers, and diabetic foot ulcers is expected to boost the demand for plasma therapy for treatment.

• For instance, according to data published by Elsevier B.V. in February 2022, the global prevalence of diabetic foot ulcers is reported to be around 6.3%. As plasma therapy helps boost tissue regeneration, leading to faster closure of chronic wounds such as DFU.

The dermatology & aesthetics segment is projected to grow at a CAGR of 8.09% over the forecast period. 

By End User

Hospitals & ASCs Segment to Lead due to Rising Cosmetic Procedures in Hospitals & ASCs

Based on hospital type, the market is segmented into hospitals & ASCs, specialty clinics, research institutes, and others.

The hospitals & ASCs segment is anticipated to witness a dominant market share over the forecast period. The segment held a 44.0% market share. The dominant share of the segment is attributed to the high volume of patients suffering from bone injuries, chronic wounds, and cosmetic procedures in hospitals & ASCs.

The specialty clinics segment is projected to grow at a CAGR of 9.04% over the forecast period. 

Plasma Therapy Market Regional Outlook

By geography, the market is categorized into Europe, North America, Asia Pacific, Latin America, and the Middle East & Africa.

North America

To get more information on the regional analysis of this market, Download Free sample

North America held the dominant share in 2024, valued at USD 246.5 million, and maintained its leading position in 2025, with a value of USD 266.3 million. The market in the region is expected to grow due to the rising prevalence of orthopedic conditions and increasing demand for cosmetic procedures, coupled with the availability of adequate treatment facilities and advanced healthcare infrastructure.

U.S. Plasma Therapy Market

Based on North America’s strong contribution and the U.S. dominance within the region, the U.S. market can be analytically approximated at around USD 246.3 million in 2025, accounting for roughly 39.7% of global plasma therapy sales.

Europe

Europe is projected to record a growth rate of 7.19% in the coming years, the second-highest among all regions, and reach a valuation of USD 158.4 million by 2025. The region’s growth in the market is driven by the increasing prevalence of wounds, cosmetic procedures, and orthopedic diseases in the region and the rising demand for plasma therapy for treatment.

U.K. Plasma Therapy Market

The U.K.’s market in 2025 is estimated to be around USD 30.47 million, representing approximately 4.9% of global plasma therapy revenues.

Germany Plasma Therapy Market

Germany’s market is projected to reach approximately USD 36.32 million in 2025, equivalent to around 5.9% of the global plasma therapy sales.

Asia Pacific

Asia Pacific is estimated to reach USD 132.2 million in 2025 and secure the position of the third-largest region in the market. In the region, India and China are both estimated to reach USD 16.94 million and USD 46.76 million, respectively, in 2025.

Japan Plasma Therapy Market

The Japan’s market in 2025 is estimated to be around USD 21.62 million, accounting for roughly 3.5% of the global plasma therapy revenues.

China Plasma Therapy Market

China’s market is projected to be one of the largest worldwide, with 2025 revenues estimated at around USD 46.76 million, representing roughly 7.5% of global plasma therapy sales.

India Plasma Therapy Market

The India’s market in 2025 is estimated to be around USD 16.94 million, accounting for roughly 2.7% of the global plasma therapy revenues.

Latin America and the Middle East & Africa

The Latin America and Middle East & Africa regions are expected to witness moderate growth in this market during the forecast period. The Latin America market is set to reach a valuation of USD 31.0 million in 2025. The increasing focus on digitalization in the region, along with the adoption of telemedicine, is expected to drive the region’s growth. In the Middle East & Africa, the GCC is set to reach a value of USD 14.0 million in 2025.

COMPETITIVE LANDSCAPE

Key Industry Players

Emphasis on Key Players to Offer Adequate Facility Management Services for Healthcare Systems

The global plasma therapy market has a semi-consolidated structure, with several players operating a wide product portfolio and maintaining a strong presence in the global scenario.

Arthrex and Stryker are prominent players in the market, offering a wide range of platelet-rich plasma products and a strong distribution network.

Other notable players, such as Zimmer Biomet, Terumo Corporation, and Crown Pharma, are strengthening their market position by increasing their focus on R&D activities for the development and introduction of advanced products in plasma therapy.

• In February 2023, Terumo Corporation announced U.S. Food and Drug Administration (FDA) clearance and launch of its IMUGARD WB Platelet Pooling Set. The set supports an extended shelf life of whole blood-derived platelets from five to seven days and acts as an alternative source of platelet supply at a time.

LIST OF KEY PLASMA THERAPY COMPANIES PROFILED

• Arthrex (U.S.)
• Zimmer Biomet (U.S.)
• Stryker (U.S.)
• Globus Medical (U.S.)
• Terumo Corporation (Japan)
• Regen Lab SA (Switzerland)
• EmCyte Corporation (S.)
• Crown Pharma (U.S.)
• BTI Biotechnology Institute (Spain)
• Celling Biosciences (U.S.)

KEY INDUSTRY DEVELOPMENTS

• July 2025: CytoChip showcased CitoCBC, the first cartridge-based Complete Blood Count (CBC) analyzer with both FDA 510(k) clearance and CLIA Waiver, and announced the launch of CitoPRP, a new cartridge-based system for platelet-rich plasma (PRP) analysis.
• May 2025: APEX Biologix announced an exclusive distribution agreement with Bioventus for the XCELL PRP system throughout the U.S. for orthopedics and sports medicine.
• November 2024: Bimini Health Tech received U.S. FDA 510k Class II clearance for its groundbreaking Platelet-Rich Plasma (PRP) preparation technology, the Float PRP.
• October 2024: PRP Labs announced the addition of EmCyte’s newest Pure TWO PRP Kits to its extensive product lineup, offering medical professionals enhanced options for platelet-rich plasma (PRP) treatments.
• July 2021: Zimmer Biomet announced that the GPS III system had completed its first treatment in mainland China, at the Boao Lecheng International Medical Tourism Pilot Zone in Lecheng.

REPORT COVERAGE

Request for Customization   to gain extensive market insights.

Report Scope & Segmentation